tiprankstipranks
ImmunityBio (IBRX)
NASDAQ:IBRX

ImmunityBio (IBRX) AI Stock Analysis

Compare
1,298 Followers

Top Page

IB

ImmunityBio

(NASDAQ:IBRX)

39Underperform
ImmunityBio's overall stock score is low due to significant financial instability, including persistent losses, high leverage, and negative cash flows. While there is some revenue growth, the company remains unprofitable, and its valuation is unattractive with a negative P/E ratio. Technical analysis indicates potential for a short-term reversal, but the overall trend is bearish.
Positive Factors
Market Expansion
ImmunityBio is expanding its market penetration by filing a BLA for BCG-unresponsive papillary NMIBC (70–80% of NMIBC cases) in 2025, with Phase 2 data in the BCG-naïve setting potentially yielding top-line results by late 2025/2026.
Strategic Collaborations
The exclusive global arrangement with the Serum Institute of India for the supply of BCG provides a key strategic advantage to IBRX given the current BCG shortage.
Negative Factors
Product Adoption Challenges
Supply of recombinant BCG is ready for shipment and is expected to increase BCG supply for physicians, addressing key hurdles for ANKTIVA's adoption.

ImmunityBio (IBRX) vs. S&P 500 (SPY)

ImmunityBio Business Overview & Revenue Model

Company DescriptionNantKwest, Inc. engages in the development of immunotherapies with a focus on harnessing the power of the innate immune system. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The firm operates through the following geographical segments: United States; Europe; and Other Non-U.S. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA.
How the Company Makes MoneyImmunityBio makes money primarily through the development and commercialization of immunotherapy products, which involve generating revenue from product sales, licensing agreements, and collaborations with other pharmaceutical companies. The company engages in partnerships to co-develop and co-market its therapeutic candidates, which can provide upfront payments, milestone payments, and royalties. Additionally, ImmunityBio may receive funding and grants from governmental or non-governmental organizations to support its research and development efforts, contributing to its revenue streams.

ImmunityBio Financial Statement Overview

Summary
ImmunityBio is facing significant financial challenges, with persistent losses, high leverage, and negative cash flows. While there is some revenue growth, the company remains heavily reliant on external financing to sustain operations. The negative equity and cash flow deficits highlight the need for improved operational efficiency and financial management to ensure long-term viability.
Income Statement
35
Negative
ImmunityBio has shown some revenue growth in the latest year, with revenue increasing from $622,000 to $14.7 million. However, the company has been consistently unprofitable, with negative net profit margins and EBIT margins over the years. The gross profit margin remains positive, but the high levels of operating losses and negative EBITDA indicate significant profitability challenges.
Balance Sheet
30
Negative
The company's balance sheet shows high leverage, with total liabilities exceeding total assets, resulting in negative stockholders' equity. This poses a risk for financial stability. The debt-to-equity ratio cannot be calculated due to negative equity, and the negative return on equity further highlights profitability issues.
Cash Flow
40
Negative
ImmunityBio's cash flow statement reflects substantial operating cash flow deficits, which have worsened over the years. The free cash flow remains negative, indicating ongoing challenges in generating cash from operations. Although the company has raised financing in previous years, the consistent negative free cash flow poses a risk to sustainability.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
14.74M622.00K240.00K934.00K605.00K
Gross Profit
14.74M622.00K-23.95M934.00K-8.54M
EBIT
-344.18M-362.25M-351.30M-330.28M-220.88M
EBITDA
-264.43M-436.18M-335.51M-315.38M-187.93M
Net Income Common Stockholders
-413.56M-583.20M-417.32M-349.85M-224.19M
Balance SheetCash, Cash Equivalents and Short-Term Investments
149.81M266.46M107.18M317.12M96.06M
Total Assets
382.93M504.45M362.36M468.91M221.38M
Total Debt
42.29M726.72M723.77M645.66M275.55M
Net Debt
-101.14M461.27M619.13M464.56M240.63M
Total Liabilities
871.06M1.09B812.18M712.82M339.87M
Stockholders Equity
-488.13M-586.99M-447.33M-242.17M-119.81M
Cash FlowFree Cash Flow
-398.12M-397.34M-436.90M-307.98M-173.39M
Operating Cash Flow
-391.24M-366.76M-337.51M-274.42M-171.72M
Investing Cash Flow
-12.25M-30.47M27.30M-84.89M-19.81M
Financing Cash Flow
281.63M558.34M233.61M505.44M150.68M

ImmunityBio Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2.87
Price Trends
50DMA
3.05
Negative
100DMA
3.72
Negative
200DMA
4.33
Negative
Market Momentum
MACD
-0.09
Positive
RSI
44.02
Neutral
STOCH
20.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IBRX, the sentiment is Negative. The current price of 2.87 is below the 20-day moving average (MA) of 3.17, below the 50-day MA of 3.05, and below the 200-day MA of 4.33, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 44.02 is Neutral, neither overbought nor oversold. The STOCH value of 20.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IBRX.

ImmunityBio Risk Analysis

ImmunityBio disclosed 95 risk factors in its most recent earnings report. ImmunityBio reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

ImmunityBio Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
50
Neutral
$95.46M-101.50%76.24%38.67%
49
Neutral
$6.90B0.02-54.05%2.46%24.91%-3.14%
44
Neutral
$114.38M-53.54%145.37%57.01%
42
Neutral
$38.57M-270.20%144.50%-141.91%
42
Neutral
$110.00M-54.21%-78.55%-0.92%
39
Underperform
$2.41B78.99%2270.58%46.82%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IBRX
ImmunityBio
2.87
-2.21
-43.50%
BLUE
Bluebird Bio
3.86
-23.94
-86.12%
FATE
Fate Therapeutics
1.01
-6.63
-86.78%
CLLS
Cellectis SA
1.30
-1.26
-49.22%
ADAP
Adaptimmune Therapeutics
0.46
-1.13
-71.07%

ImmunityBio Corporate Events

Executive/Board Changes
ImmunityBio Approves 2024 Executive Bonuses and New Incentives
Neutral
Feb 13, 2025

On February 7, 2025, ImmunityBio’s Compensation Committee approved 2024 executive bonuses for its key officers, reflecting an 80% payout of the target amount, with payments scheduled for March 14, 2025. Additionally, the company announced its 2025 Long-Term Incentive Program, granting stock options and restricted stock units to executives, with awards set to vest over three years, and set new base salary rates effective March 10, 2025.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.